Bristol-Myers Squibb Compnay

Other

Syngene International Limited

Robert F Kaltenbach, Iii

Yan Shi

Peter Tai Wah Cheng

Hao Zhang

Jun Li

Jun Shi

Shiwei Tao

James R Corte

Lawrence J Kennedy

Ying Wang

Tianan Fang

Steven J Walker

Sutjano Jusuf

Kumaravel Selvakumar

Suresh Dhanusu

Ramesh Babu Reddigunta

Robert Michael Borzilleri

John S Tokarski

David K Williams

Xiao-Tao Chen

Ramesh Badu Reddigunta

The present invention provides compounds of Formula (I): (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Cyclobutyl carboxylic acids as LPA antagonists

The present invention provides compounds of Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole carboxylic acids as LPA antagonists

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Isoxazole carboxylic acids as LPA antagonists

Cyclopentyl acids as LPA antagonists

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists

Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (Ia) and (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid triazole azines as LPA antagonists

The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, X, X, and Xare each independently CRor N; provided that no more than two of X, X, X, or Xare N; L is Calkylene substituted with 0 to 4 R; Ris (&#x2014;CH)R; a is an integer of 0 or 1; Ris each independently halo, cyano, hydroxyl, amino, Calkyl, Ccycloalkyl, Cheterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyallcyl, or haloalkoxy; n is an integer of 0, 1, or 2; Ris hydrogen, Calkyl, Cdeuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy, and the alkyl, by itself or as part of other moiety, is optionally substituted with deuterium partially or fully; Ris Calkyl, Cdeuterated alkyl, Chaloalkyl, Calkenyl, Ccycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, &#x2014;(Calkylene)-(Ccycloalkyl), &#x2014;(Calkylene)-(6 to 10-membered aryl), &#x2014;(Calkylene)-(3 to 8-membered heterocyclyl), or &#x2014;(Calkylene)-(5 to 6-membered heteroaryl); wherein each of the alkyl, alkylene, alkenyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, by itself or as part of other moiety, is independently substituted with 0 to 3 R; or alternatively, Rand R, taken together with the N atom to which they are attached, form a 4 to 9-membered heterocyclic ring moiety which is substituted with 0 to 3 R; Rand Rare each independently hydrogen, halo, cyano, hydroxyl, amino, Calkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; Ris halo, oxo, cyano, hydroxyl, amino, Calkyl, Ccycloalkyl, Cheterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; Rare each independently deuterium, halo, hydroxyl, amino, cyano, Calkyl, Cdeuterated alkyl, Calkenyl, Calkynyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl; or alternatively, two R, taken together with the atoms to which they are attached, form a 3 to 6-membered carbocyclic ring or a 3 to 6-membered heterocyclic ring each of which is independently substituted with 0 to 3 R; Ris selected from &#x2014;CN, &#x2014;C(O)OR, &#x2014;C(O)NRR, &#x2014;CO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;SO&#x2014;OH, &#x2014;SO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;P(O)(OH), tetrazol-5-yl, &#x2014;CH&#x2014;CO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;CH&#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, CH&#x2014;CO&#x2014;NH&#x2014;SO&#x2014;R, &#x2014;CH&#x2014;SO&#x2014;OH, &#x2014;CH&#x2014;SO&#x2014;NH&#x2014;CO&#x2014;R, &#x2014;CH&#x2014;P(O)(OH), tetrazol-5-ylmethylene; Ris Calkyl, Ccycloalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, or haloalkoxyalkyl; Ris hydrogen or Calkyl; and Rand Rare each independently hydrogen, Calkyl, Ccycloalkyl, Cheterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; and Ris halo, cyano, hydroxyl, amino, Calkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl. These compounds are selective LPA receptor inhibitors. 

Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists

Growing community of inventors

Holland, PA, United States of America

Robert F Kaltenbach, Iii